-
Professor Fang Liu: Unveiling the Application and Future Prospects of CAR-T Therapy in Acute Myeloid Leukemia丨13th Lu Daopei Hematology Conference
On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease Foundation, and hosted by the Beijing Lu Daopei Hematology Institute. The conference gathered world-leading hematology experts and focused on hematopoietic stem cell transplantation, cellular therapy,…
-
Professor Jiong Hu: Clinical Management of Cytomegalovirus Infection After Transplantation and the Ruijin Protocol
I. Overview of Post-Transplant Viral Infections Viral infections are among the most common complications following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and remain a major cause of infection-related mortality. Frequently…
-
Professor Peihua Lu on CD7 CAR-T丨13th Lu Daopei Hematology Conference
________________________________________ PART 1 In clinical studies and practice, particularly those pioneered by the Lu Daopei team, what efficacy potential and limitations has CD7 CAR-T shown in relapsed/refractory (r/r) T-cell malignancies?…
-
Professor Lei Fan: Prospects for Treatment Strategies in Richter’s Transformation丨2024 Nanjing Lymphoma Forum
Hematology Frontier: The 2024 Nanjing Lymphoma Forum has arrived as scheduled. As one of the executive chairs, could you introduce this year’s meeting arrangements and highlight content? Professor Lei Fan:…
-
ASCO China Voice | Prof. Yijun Shen: Intravesical PD-1 Therapy Shows Promise for High-Risk NMIBC
Oncology Frontier: What are the unmet treatment needs for high-risk NMIBC patients? Professor Yijun Shen: NMIBC has always been a focus and challenge in bladder cancer diagnosis and treatment. These…
-
3rd SPCRIS | Prof. Yang Yu: Personalized Adjuvant Therapy in HR+/HER2− Early-Stage Breast Cancer
1. Balancing Survival Benefits and Quality of Life in Extended Endocrine Therapy Oncology Frontier: Extending endocrine therapy can provide survival benefits for patients with HR+/HER2− early breast cancer, but it…
-
2025 BOC/BOA | Prof. Zhi Peng Interprets DG-04 Study: New Evidence-Based Advances in HER2 ADCs Reshape Second-Line Treatment for HER2-Positive Advance
01 Oncology Frontier: Chemotherapy, immunotherapy, and anti-HER2 regimens have formed the backbone of first-line treatment for advanced gastric cancer. However, what unmet clinical needs remain in second- and later-line treatment…
-
Prof. Xichun Hu: Two Decades of China’s Breast Cancer Research — From Imitation to Innovation, Eastern Wisdom Shines on the Global Stage
Editor’s Note: Over the past two decades, clinical research on breast cancer in China has achieved a remarkable transformation — from “following” international standards to “running alongside”, and even “leading”…
Connecting Medical Expertise through Media